Meropenem and Vaborbactam Antimicrobial Susceptibility Reference Lab

During the introductory phase of the new antimicrobial agent, meropenem and vaborbactam, the following susceptibility testing is provided by Laboratory Specialists, Inc. (LSI) to requesting U.S. clinical laboratories:

  • Contact: Laboratory Specialists, Inc. Phone: 440-835-4458 or Email:
  • Organism transport kits are provided upon request by phone or email
  • Results typically available within 48 hours of isolate receipt

Meropenem and Vaborbactam Reference Isolate Submission Form

Meropenem and Vaborbactam Antimicrobial Susceptibility Reference Lab


Meropenem and Vaborbactam Isolates for Susceptibility Testing Verification

During the introductory phase of VABOMERE (meropenem and vaborbactam), Laboratory Specialists, Inc. (LSI) will provide, upon request, a set of 30 Gram-negative isolates for susceptibility testing verification of meropenem-vaborbactam.

  • Contact: Laboratory Specialists, Inc. Phone: 440-835-4458 or Email:
  • Modal broth microdilution MIC and disk results for each of the 30 isolates will be provided along with a disk or gradient strip (MIC Test Strip; MTS) reading guide

Meropenem and Vaborbactam - Isolates Verification Request Form and Material (ISOLATES) Transfer Agreement


Oritavancin and Delafloxacin Isolate Susceptibility Testing

Thermo Fisher Scientific offers healthcare providers an Isolate Susceptibility Testing service for oritavancin and delafloxacin; results can be used for patient care purposes.

Oritavancin and Delafloxacin Isolate Submission Form

Oritavancin and Delafloxacin Isolate Testing Invoice


Educational and Scientific Grants

Melinta Therapeutics, Inc., is committed to addressing the growing threat of antimicrobial resistance (AMR) by promoting the responsible and sustainable use of its antibiotics. We support innovative research initiatives and education programs that advance medical care, foster an increased understanding of scientific, clinical, and healthcare issues that improve patient outcomes, contribute to the enhancement of patient care, and otherwise offer a broad public benefit. All requests shall be reviewed by Melinta Therapeutics for consideration. Melinta Therapeutics does not guarantee the availability of funds or approval of any grant request. Please complete the appropriate forms below and submit for consideration to:

Post Approval Research & Development Grant Form

Educational Grant Form

Budget Template


Patient Assistance Programs

The Melinta Therapeutics Patient Assistance Programs currently provide support at no cost to qualified patients who are not insured through private insurance or government-funded healthcare programs (e.g., Medicare or Medicaid). Please see links below for additional information about these programs, including eligibility criteria.


ORBACTIV® (oritavancin) Support Programs

ORBACTIV® Patient Assistance Program

Tel 844 672 2284
Fax 855 886 2482
ORBACTIV Patient Assistance Program Form


BAXDELA® (delafloxacin) Support Programs

MelintAssist Patient Assistance Program

For assistance options, call 1-844-MELINTA (1-844-635-4682).


Clinical Trials

As a research-based organization, Melinta Therapeutics is committed to researching and developing products that improve patient care and advance medicine. 

For ongoing clinical trials, visit





eGFR Calculator As calculated using the Modification of Diet in Renal Disease (MDRD) formula.



We are a community of leaders who are passionate about having a lasting impact on the wellbeing of patients, caregivers and the health care system as a whole. We are always looking for top talent to join our team.

Learn more about Career Opportunities